Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tipranavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | PGA5 | P0DJD9 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CTSE | P14091 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipranavir SCHEMBL13536854 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL6953675 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL7407890 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL5414762 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL6957763 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL29393318 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL434955 | 0.99 | MLNR (0.99) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7398499 | 0.98 | MLNR (0.96) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7398500 | 0.98 | MLNR (0.96) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7401866 | 0.98 | MLNR (0.96) | MLNRNR1I2ABCB11PGRCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19438 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2002062123-A2 | NOVEL COMPOUNDS AND METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS | YALE UNIVERSITY (US) | 2002-08-15 | — | — | WO | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| CN-1324237-A | Method for improving the pharmacokinetics of tipranavir | UPJOHN CO (US) | 2001-11-28 | — | — | CN | claimed |
| EP-1126847-A1 | METHOD FOR IMPROVING THE PHARMACOKINETICS OF TIPRANAVIR | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2001052821-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS | ABBOTT LABORATORIES (US) | 2001-07-26 | — | — | WO | claimed |
| WO-2001044508-A2 | METHOD TO EVALUATE THE SENSITIVITY OF HIV VARIANTS TO DRUGS ABLE TO INHIBIT THE HIV PROTEASE | BIOSTRANDS S.R.L. (IT) | 2001-06-21 | — | — | WO | claimed |
| EP-1109019-A1 | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease | BioStrands S.r.l. (IT) | 2001-06-20 | — | — | EP | claimed |
| US-6147095-A | ADMINISTERING COMBINATION OF TIPRANAVIR AND RITONAVIR FOR TREATMENT OF HIV | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-14 | — | — | US | claimed |
| WO-2000025784-A1 | METHOD FOR IMPROVING THE PHARMACOKINETICS OF TIPRANAVIR | PHARMACIA & UPJOHN COMPANY (US) | 2000-05-11 | — | — | WO | claimed |